Menu
Live News EQUITY H impact

DFTX Reports Positive Phase 3 Results

Definium Therapeutics announces positive topline results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet in Major Depressive Disorder

DFTX

DFTX Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder